Rapport Therapeutics, Inc.
RAPP
$38.08
$0.842.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 39.36% | 7.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.82% | 28.42% | |||
| Operating Income | 37.12% | -28.42% | |||
| Income Before Tax | 41.19% | -25.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 41.19% | -25.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 41.19% | -25.40% | |||
| EBIT | 37.12% | -28.42% | |||
| EBITDA | 37.28% | -28.64% | |||
| EPS Basic | 41.51% | -1.25% | |||
| Normalized Basic EPS | 41.52% | -1.26% | |||
| EPS Diluted | 41.51% | -1.25% | |||
| Normalized Diluted EPS | 41.52% | -1.26% | |||
| Average Basic Shares Outstanding | 0.55% | 23.85% | |||
| Average Diluted Shares Outstanding | 0.55% | 23.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||